Benetton, M.; Merli, P.; Walter, C.; Hansen, M.; Da Ros, A.; Polato, K.; Tregnago, C.; Abrahamsson, J.; Strocchio, L.; Sonneveld, E.;
et al. Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. Biomedicines 2022, 10, 1530.
https://doi.org/10.3390/biomedicines10071530
AMA Style
Benetton M, Merli P, Walter C, Hansen M, Da Ros A, Polato K, Tregnago C, Abrahamsson J, Strocchio L, Sonneveld E,
et al. Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. Biomedicines. 2022; 10(7):1530.
https://doi.org/10.3390/biomedicines10071530
Chicago/Turabian Style
Benetton, Maddalena, Pietro Merli, Christiane Walter, Maria Hansen, Ambra Da Ros, Katia Polato, Claudia Tregnago, Jonas Abrahamsson, Luisa Strocchio, Edwin Sonneveld,
and et al. 2022. "Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group" Biomedicines 10, no. 7: 1530.
https://doi.org/10.3390/biomedicines10071530
APA Style
Benetton, M., Merli, P., Walter, C., Hansen, M., Da Ros, A., Polato, K., Tregnago, C., Abrahamsson, J., Strocchio, L., Sonneveld, E., Fogelstrand, L., Von Neuhoff, N., Reinhardt, D., Hasle, H., Pigazzi, M., & Locatelli, F.
(2022). Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. Biomedicines, 10(7), 1530.
https://doi.org/10.3390/biomedicines10071530
